A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

被引：1
|
作者：
Lee, Hans C. [1 ]
Shah, Jatin J. [2 ]
Feng, Lei [3 ]
Morphey, Ashley [1 ]
Johnson, Ralph J. [1 ]
Wesson, Emily T. [1 ]
Wang, Michael L. [1 ]
Alexanian, Raymond [1 ]
Thomas, Sheeba K. [1 ]
Orlowski, Robert Z. [1 ,4 ]
Weber, Donna M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, 1515 Holcombe Blvd,Unit 429, Houston, TX 77030 USA
[2] Karyopharm Therapeut, Newton, MA USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2019年 / 94卷 / 12期
关键词：
DARATUMUMAB; POMALIDOMIDE;
D O I：
10.1002/ajh.25633
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E319 / E322
页数：4
相关论文
共 50 条
  • [31] ALL ORAL COMBINATION OF IXAZOMIB PLUS THALIDOMIDE AND DEXAMETHASONE FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA: INTERIM DATA OF AN ONGOING PHASE II TRIAL
    Ludwig, H.
    Poenisch, W.
    Knop, S.
    Schreder, M.
    Lechner, D.
    Hajek, R.
    Gunsilius, E.
    Fridrik, M.
    Petzer, A.
    Weisel, K.
    Rauch, E.
    Greil, R.
    Zojer, N.
    HAEMATOLOGICA, 2017, 102 : 110 - 110
  • [32] Combination of Bendamustine, Lenalidomide, and Dexamethasone In Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly Effective: Results of a Phase I Clinical Trial
    Lentzsch, Suzanne
    O'Sullivan, Amy
    Kennedy, Ryan
    Gill, Navkiranjit
    Andreas, Carrie
    Gardner, Diane
    Lalo, Silvana
    Burt, Steve
    Redner, Robert L.
    Volkin, Robert
    Roodman, David
    Mapara, Markus Y.
    Viverette, Frank
    Agha, Mounzer
    Zonder, Jeffrey A.
    BLOOD, 2010, 116 (21) : 435 - 435
  • [33] Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial
    Ludwig, Heinz
    Gunsilius, Eberhard
    Fridrik, Michael
    Greil, Richard
    Petzer, Andreas
    Kuehr, Thomas
    Knop, Stefan
    Schreder, Martin
    Rauch, Elisabeth
    Poenisch, Wolfram
    Zojer, Niklas
    BLOOD, 2016, 128 (22)
  • [34] Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
    Jakubowiak, Andrzej J.
    Richardson, Paul G.
    Zimmerman, Todd
    Alsina, Melissa
    Kaufman, Jonathan L.
    Kandarpa, Malathi
    Kraftson, Stephanie
    Ross, Charles W.
    Harvey, Colleen
    Hideshima, Teru
    Sportelli, Peter
    Poradosu, Enrique
    Gardner, Lesa
    Giusti, Kathy
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (04) : 472 - 480
  • [35] A MULTICENTER PHASE II CLINICAL TRIAL OF LENALIDOMIDE, MELPHALAN, PREDNISONE AND THALIDOMIDE (RMPT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Palumbo, A.
    Larocca, A.
    Sanpaolo, G.
    Falcone, A. P.
    Federico, V.
    Canepa, L.
    Crugnola, M.
    Magarotto, V.
    Cavallo, F.
    Petrucci, M. T.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 153 - 153
  • [36] Roar: A Phase Ib Trial of Oral Azacitidine in Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma (MM) Patients Refractory to Prior Lenalidomide
    Kalff, Anna
    Reed, Kate
    Khong, Tiffany T.
    Mithraprabhu, Sridurga
    Ramachandran, Malarmathy
    Hall, Richard
    Bergin, Krystal
    Spencer, Andrew
    BLOOD, 2015, 126 (23)
  • [37] Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide
    Lau, I-Jun
    Smith, Dean
    Aitchison, Robin
    Blesing, Norbert
    Roberts, Pamela
    Peniket, Andrew
    Yong, Kwee
    Rabin, Neil
    Ramasamy, Karthik
    ANNALS OF HEMATOLOGY, 2015, 94 (04) : 643 - 649
  • [38] Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide
    I-Jun Lau
    Dean Smith
    Robin Aitchison
    Norbert Blesing
    Pamela Roberts
    Andrew Peniket
    Kwee Yong
    Neil Rabin
    Karthik Ramasamy
    Annals of Hematology, 2015, 94 : 643 - 649
  • [39] A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
    Richardson, Paul G.
    Xie, Wanling
    Jagannath, Sundar
    Jakubowiak, Andrzej
    Lonial, Sagar
    Raje, Noopur S.
    Alsina, Melissa
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Munshi, Nikhil C.
    Mazumder, Amitabha
    Vesole, David H.
    Kaufman, Jonathan L.
    Colson, Kathleen
    McKenney, Mary
    Lunde, Laura E.
    Feather, John
    Maglio, Michelle E.
    Warren, Diane
    Francis, Dixil
    Hideshima, Teru
    Knight, Robert
    Esseltine, Dixie-Lee
    Mitsiades, Constantine S.
    Weller, Edie
    Anderson, Kenneth C.
    BLOOD, 2014, 123 (10) : 1461 - 1469
  • [40] Erratum: Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
    D S Siegel
    P Richardson
    M Dimopoulos
    P Moreau
    C Mitsiades
    D Weber
    J Houp
    C Gause
    S Vuocolo
    J Eid
    T Graef
    K C Anderson
    Blood Cancer Journal, 2014, 4 : e202 - e202
12345